Israel Englander’s Kyntra Bio KYNB Stock Holding History

Israel Englander’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,876	Closed	-$329K	–	6255
2023 Q2	$329K	Buy	+4,876	New	+$2.02M	﹤0.01%	4821

Other funds holding KYNB

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Israel Englander's KYNB Position: Q2 2025 in Review

Israel Englander sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 17,675 shares — an estimated $137K sold.

Israel Englander first reported a position in KYNB in Q4 2014 and held it in 36 quarters. The position peaked at $11.2M in Q1 2023. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

Israel Englander reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
Israel Englander sold 17,675 Kyntra Bio shares in Q2 2025, an estimated $137K.
Israel Englander first reported a position in Kyntra Bio in Q4 2014 and held it in 36 quarters.
Israel Englander's Kyntra Bio position peaked at $11.2M in Q1 2023.
30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.